George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.25
Bid: 19.50
Ask: 21.00
Change: 0.45 (2.31%)
Spread: 1.50 (7.692%)
Open: 19.95
High: 20.25
Low: 19.50
Prev. Close: 19.50
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Market Update

19 Jan 2021 07:00

RNS Number : 0875M
Iofina PLC
19 January 2021
 

 

19 January 2021

 

Iofina plc

("Iofina", the "Group", or the "Company")

(LSE AIM: IOF)

 

 Market Update

 

Record 2020 Iodine Production

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, today provides an update to the market regarding 2020 Group performance, a year in which it produced a record volume of crystalline iodine and continued to execute on its strategy.

 

2020 Highlights:

· Record full-year of iodine production

o Full-year 2020 production of 609.9 metric tonnes ('MT') of crystalline iodine (FY2019: 602.7MT)

o H2 crystalline iodine production of 325.5MT (H2 2019: 316MT), an increase of 14 per cent over H1, the highest production of any half-year in Company history

· IO#8 completed on time and on budget at a total cost of $3.1m

o The Company now operates five iodine production plants in western Oklahoma

· Corporate debt restructured and balance sheet greatly strengthened

o Debt significantly reduced whereby current total debt is less than half of the debt 24 months prior

o Interest rates on debt considerably reduced

· Exploration efforts for future iodine production opportunities continued and are ongoing

· Expansion of the Group's board with appointment of Mary Fallin, the recent Governor of the State of Oklahoma in the United States

· Iofina Chemical's non-iodine business remained robust

 

Commenting, President and CEO of Iofina, Dr. Tom Becker, stated: "I am delighted to announce another consecutive year of record iodine production for Iofina, with full-year 2020 production of 609.9 metric tonnes ('MT') of crystalline iodine. This production figure is testament to the dedication and resilience of our workforce and the Company which, despite being affected by the COVID-19 pandemic and a challenging macro environment, has performed strongly.

 

"Most notably during the period our newest plant IO#8 was completed on time and on budget, and a successful corporate debt restructuring has seen our balance sheet greatly strengthened, with the level of debt more than halved when compared to the figure two years ago.

 

"As we move into 2021, we are seeing increased demand and iodine sales commitments, while a recovering oil market will likely bring more drilling and workover activity than we saw in 2020, allowing us to continue delivering on our strategy to expand our iodine production. The Directors are also continuing to evaluate opportunities for both improving existing plants and constructing new plants as part of the Group's commitment to growth and increased profitability.

 

"The Company has made significant progress in 2020, it is in a stronger position than it has ever been, and the Directors look to the coming year with confidence as we exit the pandemic."

 

 

2020 production and H1 2021 forecast

In 2020 (the "Period"), the Group produced record levels of crystalline iodine (609.9 MT). H2 production of 325.5MT was the highest half-year production total in Company history. The Company continued to execute its expansion program with its newest plant, IO#8, which commenced production in April. The Group's other iodine plants performed well and with oil prices now significantly higher than mid-year 2020, Iofina and its partners expect more drilling and workover activity throughout 2021 versus 2020, which is likely to provide more brine water to produce iodine. Iofina continues to work in conjunction with its partners to maximize the supply of iodide rich brine water to each of our IOsorb® plants.

 

Iofina Resources' production forecast for H1 2021 is 285-305 MT of crystalline iodine (H1 2020: 284.4 MT). Exploration efforts are ongoing, and the Directors are carefully evaluating potential future iodine production locations as well as the overall iodine market to determine the best timing for future expansion.

 

Iodine market

Despite lower demand for iodine in H2 2020, indications in 2021 suggest that the iodine market is recovering. Iofina has already taken on significant iodine orders for 2021 which will reduce inventories. Iodine prices peaked in early 2020 and have since come off their highs but remained stable. Despite COVID, Iofina sees spot iodine prices at the beginning of 2021 to be similar to the beginning of 2020 at approximately $32.5-36/kg for large quantity buyers. Although difficult to predict, Iofina expects iodine prices to be stable in H1 2021, however this will likely be dependent on the rate of global economic recovery.

 

Diversification of products

Over several years, the Company and its Directors recognized the importance of diversification of products in our core chemical competencies. This diversification was important in 2020 as many sectors contracted. Iofina Chemical's non-iodine halogen-based products performed very well in 2020, contributing significantly to the profitability of the Group. Iofina will continue to invest in the diversification of products as it offers additional stability, particularly in difficult economic times. In 2021 Iofina Chemical plans to invest in a new production line to improve its largest non-iodine process to improve efficiencies, safety, and purity. The Group will continue to explore new products and business relationships to ensure future growth.

 

Debt refinancing

A major accomplishment in 2020 for the Group was the refinancing and reduction of debt. In September of 2020, Group debt was refinanced through First Financial Bank, Ohio. Current Group debt is less than half of debt two years ago and carries a much lower rate of interest. This allows the Group to utilize more profits to reinvest in the Company's growth.

 

COVID-19 impact

During the Period the COVID-19 pandemic had a significant impact on individuals as well as the global economy. Although the Group was not immune from the effects of this pandemic, it was not as affected as many other industries and performed well under the circumstances as management realised it needed to be more proactive during this Period.

 

At the start of the Period Iofina was on track for a breakout year with the iodine market expanding, iodine prices rising and oil production in the USA at record levels. After the economy contracted due to COVID-19, iodine demand slowed in some industries, particularly the automotive and X-ray contrast sectors, which resulted in iodine prices flattening. As a result, Iodine inventories rose in H2 2020 which is not historically atypical for Iofina's business. Further, oil companies reduced drilling and work-over programs because of lower oil prices and thus, in H2 2020, brine water available for processing at some of Iofina's plants was slightly reduced.

 

Despite all of these challenges, Iofina reacted and performed well in the Period through weathering the pandemic, and is poised for a strong 2021. The Company also has utilized and continues to explore government programs implemented to assist entities through the pandemic. Iofina also strengthened its Board of Directors by adding Mary Fallin, the most recent Governor of Oklahoma, as a Non-Executive Director.

 

IofinaEX

In H2 2020, the Director's determined that due to a number of factors including an uncertain regulatory environment, the reduction of cannabinoid prices and the need to focus in core areas, that the Group would no longer expend resources in its subsidiary IofinaEX with the exception of completing the hemp seed investment. The Company and its partners will continue seed sales efforts to maximize return on this investment without any significant expenses.

 

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +1 859 356 8000

 

Christopher Raggett/Giles Rolls/Matthew Radley (corporate finance)

Tim Redfern (ECM)

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Joe Burgess

Yellow Jersey PR Limited

Tel: +44 (0)7747 788 221

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated Company that specialises in the production of Iodine and the manufacturing of specialty chemical products. As the second largest producer of iodine in North America, it comprises three USA entities; Iofina Resources, Iofina Chemical and IofinaEX.

 

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates five producing IOsorb® plants in Oklahoma and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine based products for over 35 years.

 

IofinaEX

Iofina's newest subsidiary, IofinaEX, is fully licensed to process hemp in the state of Kentucky and holds an investment in a hemp seed production project.

 

www.iofina.com

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSFLFWAEFSEEF
Date   Source Headline
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.